Literature DB >> 7586521

Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex.

K Pettersson1, T Piironen, M Seppälä, L Liukkonen, A Christensson, M T Matikainen, M Suonpää, T Lövgren, H Lilja.   

Abstract

Generation of 15 monoclonal antibodies (MAbs) allowed construction of epitope maps and specific two-site immunofluorometric assays for free prostate-specific antigen (PSA) and PSA complexed with alpha 1-antichymotrypsin (ACT). Close correlation of PSA concentrations obtained with the use of different assays of free PSA suggested extensive similarity in immunodetection of free PSA in serum. Assays of the PSA-ACT complex overestimated the concentration of PSA-ACT in serum because of nonspecific adsorbance of ACT or cathepsin G-complexed ACT to the solid phase. This interference was substantially decreased in the presence of heparin. In studying the stability of purified PSA and PSA-ACT complexes formed in vitro, we found that the free PSA was stable during storage for 4 weeks at 35 degrees C, whereas PSA-ACT complexes largely dissociated in these conditions. The instability of PSA-ACT complexes was counteracted by storage at low temperatures, by adjusting the pH of the storage buffer between 6.8 and 7.4, and through addition of 100-1000-fold molar excess of native ACT. The ease of calibration and the accuracy of free PSA assays in comparison with assays of the PSA-ACT complex suggest that measurements of free to total PSA most accurately reflect the inverse of the proportion of PSA complexed to ACT in serum.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586521

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  24 in total

1.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

2.  PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.

Authors:  Maya B Kostova; William Nathaniel Brennen; David Lopez; Lizamma Anthony; Hao Wang; Elizabeth Platz; Samuel R Denmeade
Journal:  Prostate       Date:  2018-04-16       Impact factor: 4.104

3.  Equivalent recognition of free and ACT-complexed PSA in a monoclonal-polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody.

Authors:  Z Zhou; E G Armstrong; A Belenky; J V Freeman; K K Yeung
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.

Authors:  Oskar Vilhelmsson-Timmermand; Elmer Santos; Daniel L J Thorek; Susan Evans-Axelsson; Anders Bjartell; Hans Lilja; Steven M Larson; Sven-Erik Strand; Thuy A Tran; David Ulmert
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

5.  Stability of total and free prostate specific antigen in serum submitted to intermittent cold storage conditions.

Authors:  Asmahan A El Ezzi; Mohammed A El-Saidi
Journal:  Indian J Clin Biochem       Date:  2009-07-09

6.  Advantages of replacing the total PSA assay with the assay for PSA-alpha 1-antichymotrypsin complex for the screening and management of prostate cancer.

Authors:  J T Wu; G H Liu
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

7.  MALDI-target integrated platform for affinity-captured protein digestion.

Authors:  Asilah Ahmad-Tajudin; Belinda Adler; Simon Ekström; György Marko-Varga; Johan Malm; Hans Lilja; Thomas Laurell
Journal:  Anal Chim Acta       Date:  2013-09-11       Impact factor: 6.558

8.  Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.

Authors:  Ákos Végvári; Melinda Rezeli; Carina Sihlbom; Jari Häkkinen; Elisabet Carlsohn; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  Clin Biochem       Date:  2011-12-16       Impact factor: 3.281

9.  Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.

Authors:  Kwanghee Kim; Philip A Watson; Souhil Lebdai; Sylvia Jebiwott; Alexander J Somma; Stephen La Rosa; Dipti Mehta; Katie S Murray; Hans Lilja; David Ulmert; Sebastien Monette; Avigdor Scherz; Jonathan A Coleman
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

10.  Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).

Authors:  Mari T Peltola; Pauliina Niemelä; Kalle Alanen; Martti Nurmi; Hans Lilja; Kim Pettersson
Journal:  J Immunol Methods       Date:  2011-04-28       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.